News
7 March 2019
Cambridge Cognition appoints new Chief Operating Officer
Cambridge Cognition is pleased to announce that Dr Matthew Stork has agreed to join the Company as Chief Operating Officer on completion of the fundraise announced earlier today.
Read on
7 March 2019
Cambridge Cognition fundraising efforts generate £2.5m
Cambridge Cognition has announced that it has raised total gross proceeds of £2.5 million through an oversubscribed placing of 3,437,500 new ordinary shares (“Placing Shares”) of 1 pence each in the capital of the Company (“Ordinary Shares”) at a price of 72 pence per Ordinary Share (the “Issue Price”); and a subscription for 34,723 Ordinary Shares (the “Subscription Shares”) also at the Issue Price (the “Subscription”) (the Subscription and the Placing together, the “Fundraising”).
finnCap Ltd and Dowgate Capital Limited acted as joint bookrunners to the Company (the “Bookrunners”).
Read on
7 March 2019
Cambridge Cognition sales orders up 49% to £7.93m
Cambridge Cognition announced preliminary results for the year ended 31 December 2018 with sales orders up 49% to £7.93m.
Read on
31 January 2019
Cambridge Cognition announces first partnership in India
Cambridge Cognition has announced a partnership with a major pharmaceutical company to deliver online neurological testing to patients in India using the Company’s cloud-based CANTAB Connect platform.
Read on
14 November 2018
Cambridge Cognition signs new eCOA contracts
Cambridge Cognition today announced it has won a significant new phase IV clinical trial contract for use of its electronic clinical outcomes assessment (eCOA) platform, CANTAB Connect.
Read on
13 September 2018
NeuroVocalix platform ready for clinical trials
NeuroVocalix enables novel voice-based cognitive assessments to be delivered directly to patients through mobile and tele-health platforms, helping to improve outcomes in clinical trials, aid clinical decision-making and play an important role in the management of long-term conditions such as chronic pain.
